TY  - JOUR
AU  - Andorrà, Magí
AU  - Alba-Arbalat, Salut
AU  - Camos-Carreras, Anna
AU  - Gabilondo, Iñigo
AU  - Fraga-Pumar, Elena
AU  - Torres-Torres, Ruben
AU  - Pulido-Valdeolivas, Irene
AU  - Tercero-Uribe, Ana I
AU  - Guerrero-Zamora, Ana M
AU  - Ortiz-Perez, Santiago
AU  - Zubizarreta, Irati
AU  - Sola-Valls, Nuria
AU  - Llufriu, Sara
AU  - Sepulveda, Maria
AU  - Martinez-Hernandez, Eugenia
AU  - Armangue, Thais
AU  - Blanco, Yolanda
AU  - Villoslada, Pablo
AU  - Sanchez-Dalmau, Bernardo
AU  - Saiz, Albert
AU  - Martinez-Lapiscina, Elena H
PY  - 2020
DO  - 10.1001/jamaneurol.2019.3283
UR  - https://hdl.handle.net/10668/25323
T2  - JAMA neurology
AB  - Neuroprotective and remyelinating therapies are required for multiple sclerosis (MS), and acute optic neuritis (AON) is a potential condition to evaluate such treatments. To comprehensively assess key biological and methodological aspects of AON...
LA  - en
KW  - Adult
KW  - Evoked Potentials, Visual
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Multiple Sclerosis
KW  - Neuroprotective Agents
KW  - Optic Neuritis
KW  - Prospective Studies
KW  - Remyelination
KW  - Tomography, Optical Coherence
KW  - Visual Acuity
TI  - Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis.
TY  - research article
VL  - 77
ER  -